Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Acquired Immunodeficiency Syndrome 12HIV Infections 11Sarcoma, Kaposi 9Lymphoma 5Lymphoma, Non-Hodgkin 2AIDS-Related Opportunistic Infections 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Multi-centric Castleman's Disease 1Leukemia-Lymphoma, Adult T-Cell 1Herpesviridae Infections 1Epstein-Barr Virus Infections 1Dendritic Cell Sarcoma, Interdigitating 1Cytomegalovirus Infections 1Castleman Disease 1AIDS-Related Complex 1

Interventions

tocilizumab 1tanespimycin 1siltuximab 1Zidovudine 1Valganciclovir 1Polymerase Chain Reaction 1Histological Techniques 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Multi-centric Castleman's Disease × Zidovudine × Clear all
NCT01441063 2020-10-27

Tocilizumab for KSHV-Associated Multicentric Castleman Disease

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
8 enrolled 18 charts
LymphoidSarcoma

Multi-centric Castleman's Disease, Acquired Immunodeficiency Syndrome, Castleman Disease, Sarcoma, Kaposi

Data powered by HemOnc (CC BY 4.0) Colophon âš¡